selected publications
- Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction. Bioorganic & medicinal chemistry letters. 2024 Academic Article GET IT
- Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches. Journal of personalized medicine. 2024 Review GET IT
- Discovery of ICOS-targeted small molecules using pharmacophore-based screening. ChemMedChem. 2023 Academic Article GET IT
-
Molecular signature associated with cladribine treatment in patients with multiple sclerosis.
Frontiers in immunology.
2023
Academic Article
GET IT
Times cited: 1 - Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells. International journal of molecular sciences. 2023 Review GET IT
-
Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2022
Academic Article
GET IT
Times cited: 3 -
Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.
Clinical and translational medicine.
2022
Letter
GET IT
Times cited: 123 -
Immunomodulatory Effects Associated with Cladribine Treatment.
Cells.
2021
Academic Article
GET IT
Times cited: 14 -
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
Multiple sclerosis (Houndmills, Basingstoke, England).
2021
Academic Article
GET IT
Times cited: 1 -
Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2021
Academic Article
GET IT
Times cited: 19 -
How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process.
Gut microbes.
2020
Academic Article
GET IT
Times cited: 23 -
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2020
Academic Article
GET IT
Times cited: 6 -
Chitinase 3-like 1 is neurotoxic in primary cultured neurons.
Scientific reports.
2020
Academic Article
GET IT
Times cited: 23 -
A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis.
Cells.
2020
Academic Article
GET IT
Times cited: 30 -
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
The American journal of pathology.
2018
Academic Article
GET IT
Times cited: 16 -
Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.
Autoimmunity reviews.
2017
Review
GET IT
Times cited: 67 -
Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation.
Brain, behavior, and immunity.
2017
Review
GET IT
Times cited: 20 -
Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.
Molecular neurobiology.
2016
Academic Article
GET IT
Times cited: 21 -
Metabolic responses of CHO cells to limitation of key amino acids.
Biotechnology and bioengineering.
2014
Academic Article
GET IT
Times cited: 63 -
Metabolic signatures of GS-CHO cell clones associated with butyrate treatment and culture phase transition.
Biotechnology and bioengineering.
2013
Academic Article
GET IT
Times cited: 68